# Woori Venture Partners

> Woori Venture Partners is a VC fund backing Artificial Intelligence. See 64 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Seongnam, South Korea
- Total investments: 64
- Last investment: Jul 2026
- Lead investor: 11%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/woorivp-us
- Website: http://www.woorivp.com/home/en/main/main.do

Woori Venture Partners is an investment firm.

## Contacts

5 contacts available for Woori Venture Partners. Shizune tracks 2 team members at Woori Venture Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/woori-venture-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.9M–$33M |
| Series B | $4.8M–$73M |
| Series C | $3.5M–$122M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 15 | 23% |
| Software | 12 | 19% |
| Biotechnology | 10 | 16% |
| Pharmaceutical | 8 | 13% |
| Health Care | 7 | 11% |

84 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 19 | 30% |
| Series B | 16 | 25% |
| Series C | 9 | 14% |
| Seed | 6 | 9% |
| Venture - Series Unknown | 5 | 8% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| South Korea | 42 | 66% |
| United States | 5 | 8% |
| Singapore | 4 | 6% |
| India | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Choi Hyung-seok | Team Leader | 1 | https://shizune.co/investors/profile/choi-hyung-seok |
| Kim Man-sik | Team Leader | 1 | https://shizune.co/investors/profile/kim-man-sik |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Prazer Therapeutics | Prazer Therapeutics assists patients suffering from intractable diseases through the use of logical and innovative drug design approaches. They willaccomplished this through the use of new and innovative drug development platforms, such as rational molecular drug design technology and next-generation protein degradation technology. | $33.9M | Venture - Series Unknown | Jul 23, 2026 |  |
| ArcGen Bioscience | ArcGen Bioscience is a biopharmaceutical development company focused on researching, developing, and advancing innovative therapeutic solutions to address unmet medical needs through cutting-edge biotechnology and drug development. | $6.7M | Series A | Jul 13, 2026 |  |
| PROMEDIUS | Promedius is a MedTech startup, based in Seoul, Korea, focusing on optimizing radiologists workflow of medical imaging interpretation to drive improved patient outcomes. Our platform, AIdant, is providing an AI-enabled medical imaging cloud solution for individual doctors, medical institutions, and teleradiology centers. We believe ourcomprehensive zero-footprint AI solution can cover the geographic issues, after-hour issues, and lack of the radiologists issue in the diagnostic imaging market. | $14M | Series B | Jun 05, 2026 |  |
| Unastella | Unastella is an aerospace company developing human spaceflight technologies, including launch vehicles and suborbital tourism systems. The company focuses on advancing reusable rocket technology and future space travel infrastructure for civilian space exploration missions. Unastella aims to support the growth of private human spaceflight andnext-generation aerospace innovation. | $22.2M | Series B | Jun 01, 2026 |  |
| Upstage | Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $380.2M | Venture - Series Unknown | May 03, 2026 |  |
| Upstage | Upstage AI develops artificial intelligence technologies focused on large language models and document processing systems designed to support enterprise workflows. Its platform includes tools that convert unstructured data such as PDFs, scans, and emails into structured, machine-readable formats, enabling downstream analysis and automation. Thecompany also provides models like its Solar LLM, which are optimized for tasks such as text generation, information extraction, and question answering within business environments. Its solutions are applied across industries including finance, healthcare, insurance, and manufacturing to handle tasks like document parsing, data extraction, and workflow automation. Additionally, its services can be deployed through APIs, cloud environments, or on-premise systems to integrate with existing enterprise infrastructure. | $121.7M | Series C | Apr 15, 2026 |  |
| BreezeBio | GenEdit was founded to transform the delivery of gene therapies and enable the next generation of non-viral, gene editing-based therapeutics. GenEdit’s proprietary technology, NanoGalaxy™ platform solves current delivery challenges by systematically screening its nanoparticle library and providing safer and efficient delivery to target tissues. Thecompany's tool makes therapeutic gene editing possible and is easier to use, faster and more accurate than previous gene-editing techniques and thus has the potential for a wide range of therapeutic applications, enabling physicians to cure incurable genetic diseases. | $60M | Series B | Feb 25, 2026 |  |
| BOS Semiconductors | BOS Semiconductors is a fabless semiconductor firm specializing in automotive-grade System-on-Chip (SoC) solutions and high-performance computing platforms. Its technologies support advanced driver assistance, autonomous driving, and centralized in-vehicle computing systems. | $60.3M | Series A | Feb 23, 2026 |  |
| Orum Therapeutics | Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies targeting cytosolic proteins for unmet medical needs in cancer and rare diseases. Orum leverages its unique cell-penetrating antibody platform, called Oromab™ to inhibit drug targets, previously undruggable by small molecules or current antibodytherapeutics. In contrast to other approaches, Orum’s antibody platform can intracellularly deliver an active antibody therapeutic or payload, is easily adaptable to target different cell types and intracellular proteins, and does not require chemical modification. | $98.3M | Post-IPO Equity | Dec 18, 2025 |  |
| Share It | Share It is an IT social network platform that offers space mediation services for idle schools. | $5.4M | Series C | Dec 02, 2025 |  |

10 of 64 investments shown.

## Co-investors
- [Korea Development Bank](https://shizune.co/investors/profile/korean-development-bank) — VC Fund, 12 deals together
- [Industrial Bank of Korea](https://shizune.co/investors/profile/industrial-bank-of-korea) — VC Fund, 11 deals together
- [KB Investment](https://shizune.co/investors/profile/kbinvest) — VC Fund, 11 deals together
- [Hana Ventures](https://shizune.co/investors/profile/hana-ventures) — VC Fund, 10 deals together
- [Smilegate Investment](https://shizune.co/investors/profile/smilegate-investment) — VC Fund, 10 deals together
- [Company K Partners](https://shizune.co/investors/profile/company-k) — VC Fund, 9 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Artificial intelligence Investors in South Korea](https://shizune.co/investors/artificial-intelligence-investors-south-korea)
- [Artificial intelligence VC Funds in South Korea](https://shizune.co/investors/artificial-intelligence-vc-funds-south-korea)
- [Medical VC Funds in South Korea](https://shizune.co/investors/medical-vc-funds-south-korea)
- [Medical Device Investors in South Korea](https://shizune.co/investors/medical-device-investors-south-korea)
- [Medical Device VC Funds in South Korea](https://shizune.co/investors/medical-device-vc-funds-south-korea)
- [Sports Investors in South Korea](https://shizune.co/investors/sports-investors-south-korea)

## FAQ

### What does Woori Venture Partners invest in?

Woori Venture Partners invests primarily in Artificial Intelligence, Software and Biotechnology startups, most often at Series A and Series B stage. Most of the 64 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Woori Venture Partners's check size?

Woori Venture Partners typically joins rounds of $2.9M–$33M at Series A, $4.8M–$73M at Series B and $3.5M–$122M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Woori Venture Partners participates in.

### How do I contact Woori Venture Partners?

Public channels for Woori Venture Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Woori Venture Partners?

The team at Woori Venture Partners includes Choi Hyung-seok (Team Leader) and Kim Man-sik (Team Leader). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co